Статья
Клеточные и молекулярные механизмы формирования кальцинирующей болезни аортального клапана
В обзоре приведены современные данные о патогенезе кальцинирующей болезни аортального клапана (КБАК) – широко распространенном заболевании с неблагоприятным прогнозом. В настоящее время отсутствуют эффективные терапевтические методы профилактики и лечения данной патологии за исключением операции по замене клапана. Рассмотрена роль генетических и наследственных факторов в возникновении КБАК, ведущие патогенетические механизмы описаны с учетом стадии заболевания. В частности, в фазе инициации кальциноза ведущую роль играют процессы депонирования окисленных липопротеинов в створках клапана и локальное воспаление. В фазе прогрессирования доминирует активная эктопическая кальцификация подобная процессу формирования костной ткани. Изучение патогенеза КБАК представляется целесообразным с точки зрения перспективы разработки новых эффективных лечебно-профилактических подходов.
1. Peeters FECM, Meex SJR, Dweck MR, et al. Calcific aortic valve stenosis: hard disease in the heart: A biomolecular approach towards diagnosis and treatment. Eur Heart J. 2018;39(28):2618-24. doi:10.1093/eurheartj/ehx653.
2. Lucena CM, Santos RP. Association between Aortic Valve Sclerosis and Adverse Cardiovascular Events. Arq Bras Cardiol. 2015;105(1):99. doi:10.5935/abc.20150081.
3. Hudzik B, Wilczek K, Gasior M. Heyde syndrome: gastrointestinal bleeding and aortic stenosis. CMAJ. 2016;188(2):135-8. doi:10.1503/cmaj.150194.
4. Moncheberg JG. Der normale histologischeBau und die ScleroseAortenklappen. Virchows Archiv fur pathologische Anatomie und Physiology und fur Klinische Medizin. 1904;176:472-96. doi.org/10.1007/bf02041318.
5. Егоров И. В., Шостак Н. А., Артюхина Е. А. Аортальный стеноз дегенеративного генеза — проблема на пересечении мнений. Российский кардиологический журнал. 1999;4:50-3.
6. Braunwald E. Heart Disease: A Textbook of Cardiovascular Medicine (Volume 2) — Philadelphia: W. B. Saunders Company; 1988. 13-41 p. ISBN-10: 0721619541 ISBN-13: 978-0721619545.
7. Hulin A, Hego A, Lancellotti P, et al. Advances in pathophysiology of calcific aortic valve disease propose novel molecular therapeutic targets. Front Cardiovasc Med. 2018;5:21. doi:10.3389/fcvm.2018.00021.
8. Rajamannan NM, Moura L. The lipid hypothesis in calcific aortic valve disease: the role of the multi-ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol. 2016;36:774-6. doi:10.1161/ATVBAHA.116.307435.
9. Coffey S, Cox B, Williams MJ. The prevalence, incidence, progression, and risks of aortic valve sclerosis: a systematic review and meta-analysis. J Am Coll Cardiol. 2014;63(25):2852-61. doi:10.1016/j.jacc.2014.04.018.
10. Sathyamurthy I, Alex S. Calcific aortic valve disease: is it another face of atherosclerosis? Indian heart journal. 2015;67(5):503-6. doi:10.1016/j.ihj.2015.07.033.
11. Ferreira-Gonzalez I, Pinar-Sopena J, Ribera A et al. Prevalence of calcific aortic valve disease in the elderly and associated risk factors: a population-based study in a Mediterranean area. Eur J Prev Cardiol. 2013;20(6):1022-30. doi:10.1177/2047487312451238.
12. Ye C, Xu M, Wang S, et al. Decreased Bone Mineral Density Is an Independent Predictor for the Development of Atherosclerosis: A Systematic Review and Meta-Analysis. PLoS One. 2016;11(5):e0154740. doi:10.1371/journal.pone.0154740.
13. Parisi V, Leosco D, Ferro G, et al. The lipid theory in the pathogenesis of calcific aortic stenosis. Nutrition, Metabolism & Cardiovascular Diseases. 2015;25:519-25. doi:10.1016/j.numecd.2015.02.001.
14. Rajamannan NM. Oxidative-mechanical stress signals stem cell niche mediated Lrp5 osteogenesis in eNOS(-/-) null mice. J Cell Biochem. 2012;113(5):1623-34. doi:10.1002/jcb.24031.
15. Nadlonek NA, Lee JH, Weyant MJ. ox-LDL induces PiT-1 expression in human aortic valve interstitial cells. J Surg Res. 2013;184:6-9. doi:10.1016/j.jss.2013.05.001.
16. Mohty D, Pibarot P, Despres JP. Association between plasma LDL particle size, valvular accumulation of oxidized LDL and inflammation in patients with aortic stenosis. Arterioscler Thromb Vasc Biol. 2008;28:187-93. doi:10.1161/ATVBAHA.107.154989.
17. Smith J, Luk GK, Schulz CA, et al. Cohorts for heart and aging research in genetic epidemiology (CHARGE) extracoronary calcium working group. Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis. J Am Med Assoc. 2014;312:1764-71. doi:10.1001/jama.2014.13959.
18. Olgun Kucuk H, Kucuk U, Demirtaş C, Ozdemir M. Role of serum high density lipoprotein levels and functions in calcific aortic valve stenosis progression. Int J Clin Exp Med. 2015;8(12):22543-9.
19. Lommi JI, Kovanen T, Jauhiainen M. High-density lipoproteins (HDL) are present in stenotic aortic valves and may interfere with the mechanisms of valvular calcification. Atherosclerosis. 2011;219(2):538-44. doi:10.1016/j.atherosclerosis.2011.08.027.
20. El Accaoui RN, Gould ST, Hajj GP, et al. Aortic valve sclerosis in mice deficient in endothelial nitric oxide synthase. Am J Physiol Heart Circ Physiol. 2014;306:H1302-13. doi:10.1152/ajpheart.00392.2013.
21. Audet A, Cote N, Couture C, et al. Amyloid substance within stenotic aortic valves promotes mineralization. Histopathology. 2012;61:610-9. doi:10.1111/j.1365-2559.2012.04265.x.
22. Trapeaux J, Busseuil D, Shi Y, et al. Improvement of aortic valve stenosis by ApoA-I mimetic therapy is associated with decreased aortic root and valve remodelling in mice. Br J Pharmacol. 2013;169(7):1587-99. doi:10.1111/bph.12236.
23. Dimitrow PP. Aortic stenosis: new pathophysiological mechanisms and their therapeutic implications. Pol Arch Med Wewn. 2014;124(12):723-30. doi:10.20452/pamw.2562.
24. Ardehali R, Leeper NJ, Wilson AM, et al. The effect of angiotensin-converting enzyme inhibitors and statins on the progression of aortic sclerosis and mortality. J Heart Valve Dis. 2012;21(3):337-43.
25. Akin I, Nienaber CA. Is there evidence for statins in the treatment of aortic valve stenosis? World J Cardiol. 2017;9(8):667-72. doi:10.4330/wjc.v9.i8.667.
26. De Vecchis R, Di Biase G, Esposito C, et al. Statin use for nonrheumatic calcific aortic valve stenosis: a review with meta-analysis. J Cardiovasc Med (Hagerstown). 2013;14(8):55967. doi:10.2459/JCM.0b013e3283587267.
27. Chan KL, Teo K, Dumesnil JG, et al. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation. 2010;121:306-14. doi:10.1161/circulationaha.109.900027.
28. Чумакова О. С., Селезнева Н. Д., Евдокимова М. А. и др. Прогностическое значение аортального стеноза у больных, перенесших обострение ишемической болезни сердца. Кардиология. 2011;51(1):23-31.
29. Bonetti A, Marchini M, Ortolani F. Ectopic mineralization in heart valves: new insights from in vivo and in vitro procalcific models and promising perspectives on noncalcifiable bioengineered valves. J Thorac Dis. 2019;11(5):2126-43. doi:10.21037/jtd.2019.04.78.
30. New SE, Aikawa E. Molecular imaging insights into early inflammatory stages of arterial and aortic valve calcification. Circ Res. 2011;108:1381-91. doi:10.1161/circresaha.110.234146.
31. Kim KM. Calcification of matrix vesicles in human aortic valve and aortic media. Fed Proc. 1976;35:156-62.
32. Mohler ER, Gannon F, Reynolds C, et al. Bone formation and inflammation in cardiac valves. Circulation. 2001;103:1522-30. doi:10.1161/01.CIR.103.11.1522.
33. Peltonen T, Napankangas J, Ohtonen P, et al. (Pro)renin receptors and angiotensin converting enzyme 2/angiotensin-(1-7)/Mas receptor axis in human aortic valve stenosis. Atherosclerosis. 2011;216:35-43. doi:10.1016/j.atherosclerosis.2011.01.018.
34. Capoulade R, Clavel MA, Mathieu P, et al. Impact of hypertension and renin-angiotensin system inhibitors in aortic stenosis. Eur J Clin Invest. 2013;43:1262-72. doi:10.1111/eci.12169.
35. Kostyunin AE, Yuzhalin AE, Ovcharenko EA, et al. Development of calcific aortic valve disease: Do we know enough for new clinical trials? J Mol Cell Cardiol. 2019;132:189-209. doi:10.1016/j.yjmcc.2019.05.016.
36. Leopold JA. Cellular mechanisms of aortic valve calcification. Circ Cardiovasc Interv. 2012;5(4):605-14. doi:10.1161/circinterventions.112.971028.
37. Towler DA. Molecular and cellular aspects of calcific aortic valve disease. Circ Res. 2013;113(2):198-208. doi:10.1161/circresaha.113.300155.
38. Qua X, Huanga X, Jin F. Bone mineral density and all-cause, cardiovascular and stroke mortality: A meta-analysis of prospective cohort studies. Int J Cardiol. 2013;166(2):38593. doi:10.1016/j.ijcard.2011.10.114.
39. Patel KK, Shah SY, Arrigain S, et al. Characteristics and outcomes of patients with aortic stenosis and chronic kidney disease. J Am Heart Assoc. 2019;8(3):e009980. doi:10.1161/JAHA.118.009980.
40. Dweck MR, Khaw HJ, Sng GKZ, et al. Aortic stenosis, atherosclerosis, and skeletal bone: is there a common link with calcification and inflammation? Eur Heart J. 2013;34(21):156774. doi:10.1093/eurheartj/eht034.
41. Pawade TA, Newby DE, Dweck MR, et al. Calcification in Aortic Stenosis: J Am Coll Card. 2015;66(5):561-77. doi:10.1016/j.jacc.2015.05.066.
42. Debiec R, Sall H, Samani N, et al. Genetic insights into bicuspid aortic valve disease. Cardiology in Review. 2017;25(4):158-64. doi:10.1097/CRD.0000000000000147.
43. Probst V, Le Scouarnec S, Legendre A, et al. Familial aggregation of calcific aortic valve stenosis in the western part of France. Circulation. 2006;113:856-60. doi:10.1161/circulationaha.105.569467.
44. Lee SP. Understanding the Natural History of Bicuspid Aortic Valve: Are We Close to Understanding It? J Cardiovasc Imaging. 2019;27(2):119-21. doi:10.4250/jcvi.2019.27.e21.
45. Kutikhin AG, Yuzhalin AE, Brusina EB, et al. Genetic predisposition to calcific aortic stenosis and mitral annular calcification. Mol Biol Rep. 2014;41(9):5645-63. doi:10.1007/s11033-014-3434-9.
46. University of Edinburgh. Study Investigating the Effect of Drugs Used to Treat Osteoporosis on the Progression of Calcific Aortic Stenosis (SALTIRE II). 2014. https://clinicaltrials.gov/ct2/show/NCT02132026 (May 27, 2014).
47. Kang TS, Park S. Antihypertensive Treatment in Severe Aortic Stenosis. J Cardiovasc Imaging. 2018;26(2):45-53. doi:10.4250/jcvi.2018.26.e9.